Hims, Super Bowl and Hers

Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
Hims & Hers' Super Bowl ad turns up the heat on GLP-1 battle
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the pharma industry, lawmakers and some industry groups. | Hims & Hers hit the bullseye with its Super Bowl ad,
Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs
The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.
Hims & Hers aired a Super Bowl ad for weight loss drugs. It alarmed health experts and senators.
In response to complaints made publicly by the Partnership for Safe Medicine and the Obesity Society, Hims & Hers provided Yahoo Life with the following statement: This is a clear attempt by industry groups to cancel an advertisement that directly calls out how they are part of a system that fails to prioritize the health of Americans.
Hims & Hers Super Bowl commercial: Ad draws ire from drug industry
Hims & Hers makes its Super Bowl commercial debut in 2025 with a spot for the telehealth company's weight loss medications. Set to the "This Is America" by Childish Gambino (Donald Glover), the commercial calls out weight loss prescriptions and the weight-loss industry that "feeds on our failure."
Hims & Hers Super Bowl Spot Draws Drug-Industry Backlash
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto against weight-loss treatments priced “for profits, not patients,” after critici
Doctor weighs in on controversial weight loss drug commercial
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr.
Hims & Hers Super Bowl Ad Controversy - Here's The Latest
Hims & Hers faced backlash over its Super Bowl ad touting its compound weight loss drug while slamming pharmaceutical giants for profiting from America's obesity crisis. The company attracted flak from US Senators,
Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
Hims & Hers markets itself in a very 2025 way: by picking a fight
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Hims & Hers: Firing On All Cylinders, But Expensive
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers Option Trade Offers $410 Return Or 17% Discount
The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the ...
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Zacks.com on MSN1d
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...